The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Biological and therapeutic impact of tumor mutational burden in microsatellite instability/mismatch repair-deficient (MSI/dMMR) metastatic colorectal cancer (mCRC) treated with immune checkpoint inhibitors (ICI).
 
Sarah Blanchet Deverly
No Relationships to Disclose
 
Balthazar Raffy
No Relationships to Disclose
 
Toky Ratovomanana
Patents, Royalties, Other Intellectual Property - Chief technology officer at MSInsight
 
Remy Nicolle
No Relationships to Disclose
 
Paula Nay
No Relationships to Disclose
 
Thierry Andre
Honoraria - Bristol-Myers Squibb; Merck; Merck Serono; Sanofi; Seagen; SERVIER
Consulting or Advisory Role - Abbvie; Aptitude Health; Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline; MSD Oncology; Nimbus Therapeutics; Nordic Bioscience; Pfizer; Seagen; SERVIER; Takeda
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD Oncology; Takeda
Other Relationship - Inspirna
(OPTIONAL) Uncompensated Relationships - Adjuvant Colon Cancer End Points (ACCENT) Collaborative Group; ARCAD Foundation; ARCAD Foundation
 
Alex Duval
No Relationships to Disclose
 
Romain Cohen
Honoraria - AstraZeneca/Daiichi Sankyo; AstraZeneca/Daiichi Sankyo; Bristol-Myers Squibb; Bristol-Myers Squibb; MSD Oncology; Mylan; Pierre Fabre; SERVIER; SERVIER; SERVIER
Consulting or Advisory Role - Bristol-Myers Squibb; Enterome; Exeliom Biosciences
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; MSD Oncology; Mylan; SERVIER; SERVIER